FIG 3.

Kill curve activity of simulations for CFZ administered at 2 g every 8 h and OXA administered at 2 g every 6 h in an ex vivo SEV model in host-mimicking RPMI–10% LB media against MRSA strains 11-11 (A), MW2 (B), COL (C), and BMC-1001 (D). *, P < 0.05 versus control.